Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > No substance

<< Previous

Bullboard Posts

Next >>

Post by Jshaw9on Mar 04, 2021 10:04am

106 Views

Post# 32714018

No substance

The problem with all the news releases is that none of them have any substance to them. They're all what they want to do, what they plan to do, what they airm to do... but nothing in regards to what they are currently doing or if they've accomplished anything.
everyone saying that they can't fit all the news over the last 8 months into one... sure they can. "Over the past 8 months we've been able to accomplish ______"
until they can show us some kind of success with their own products or something of merit, this stock is going nowhere

<< Previous

Bullboard Posts

Next >>

This AI stock is disrupting the event tickets monopoly